ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Tripos, a supplier of drug discovery informatics products, has agreed to acquire Pharsight, a provider of software and services designed to optimize clinical drug development, for $57 million. "The fusion of the design and analysis tools from Tripos and Pharsight will allow us to bring greater value to our customers engaged in the pharmaceutical research and development process," says Tripos CEO Jim Hopkins. Meanwhile, Phase Forward, a developer of software used in collecting drug trial information, has acquired Clarix, a provider of Web-based interactive response technology, for $40 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter